

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.

# STRUCTURAL MODIFICATIONS OF 6-NAPHTHALENE-2-CARBOXYLATE RETINOIDS

Kuo-Long Yu,\* Jacek Ostrowski,+ Simon Chen,+ Kenneth M. Tramposch,+  
Peter R. Reczek,+ Muzammil M. Mansuri, and John E. Starrett Jr.


Bristol-Myers Squibb Company, Pharmaceutical Research Institute  
5 Research Parkway, Wallingford, Connecticut 06492

+ Westwood-Squibb Pharmaceuticals, 100 Forest Avenue, Buffalo, New York 14213

**Abstract** The keto linker of 2-naphthoate retinoid **1** has been found nonessential for RAR transactivation activity and can be replaced with heteroatoms such as S, O, N without significant reduction of the activity. On the other hand, substitutions on the aromatic rings of retinoids **1** and **2** resulted in analogs with reduced potency and RAR selectivity.  
Copyright © 1996 Elsevier Science Ltd


We have previously demonstrated that the naphthalene ring of **1** and **2** is important for their potency and retinoic acid receptor selectivity.<sup>1</sup> In this study, we investigated the effects of substituents at varied positions of the aromatic rings of retinoids **1** and **2** (Chart 1), and replacement of the keto or the alcohol linker between the aromatic rings with heteroatoms (Chart 2).

Chart 1



Compd No.	X,Y	R1	R2	R3	R4	Compd No.	X,Y	R1	R2	R3	R4
1	O	H	H	H	H	9	O	H	H	F	H
2	OH,H	H	H	H	H	10	O	H	H	H	OMe
3	O	F	OH	H	H	11	O	H	H	H	OH
4	O	OMe	H	H	H	12	OH,H	F	H	H	H
5	O	H	OH	H	H	13	OH,H	H	OH	H	H
6	O	H	Me	H	H	14	OH,H	H	Me	H	H
7	O	H	F	H	H	15	OH,H	H	F	H	H
8	O	H	OMe	H	H	16	OH,H	H	H	F	H

The synthesis of these substituted naphthoate derivatives is shown in Schemes 1 and 2. To prepare the 1'-fluoro substituted derivatives **3** and **12** (Scheme 1A), *m*-fluorophenol was treated with 2,5-dimethyl-2,5-hexanediol in the presence of aluminium chloride to afford fluorophenol **17**. The phenol was protected as a methyl ether, which was acylated with naphthalene-2,6-dicarboxylate monomethyl ester acid chloride (**18**), accompanied with the hydrolysis of the methyl ether, to give **19**. It is worth noting that without protection of the phenol, the Friedel-Crafts reaction gave only the recovered starting material. Ester **19** can be hydrolyzed to give retinoid **3** or dehydroxylated by converting the phenol to a triflate, followed by reduction with ammonium formate in the presence of palladium acetate and triphenylphosphine.<sup>2</sup> Reduction of the ketone with sodium borohydride and hydrolysis of the ester provided retinoid **12**. In a similar approach (Scheme 1B), phenol **20**<sup>3</sup> was dehydroxylated to provide **21** using the triflation-reduction procedure described above, except that the reduction was performed in a Parr apparatus using H<sub>2</sub>-Pd/C.<sup>4</sup> Reduction of the triflate with the formate or triisopropyl silane gave no reaction. Early attempts to acylate **21**


Scheme 1<sup>a</sup>

(a)  $((CH_3)_2COHCH_2)_2$ ;  $AlCl_3$ ; (b) NaH, MeI; (c) 18,  $AlCl_3$ ; (d) NaOH; (e)  $Tf_2O$ , DIEA or pyridine; (f)  $HCOOH$ ,  $Et_3N$ ,  $Pd(OAc)_2$ ,  $PPh_3$ ; (g)  $NaBH_4$ ; (h) 10% Pd/C,  $H_2$ ,  $Et_3N$ ; (i)  $Br_2$ , AcOH; (j)  $t-BuLi$ ; 18; (k) 25.

with 18 gave a 3'-methoxy acylated compound (24a) rather than 1'-methoxy product due to Lewis acid catalyzed rearrangement of 20 to the more stable 2-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene. Saponification of this side product yielded 3'-methoxy substituted retinoid 8. Alternatively, 21 was treated with bromine in acetic acid<sup>5</sup> to provide a mixture of 2-brominated and 4-brominated products in a 2:1 ratio. The 2-brominated naphthol (22) was separated by silica gel chromatography, eluting with hexane and ethyl acetate (2:1), and then treated with *t*-butyl lithium, followed by addition of acid chloride 18 to provide 23. Saponification of 23 yielded 4. For 3'-hydroxy, 3'-methyl- or 3'-fluoro derivatives (5-7, and 13-15), the synthesis was straightforward, and shown in Scheme 1C. To prepare 4'-fluoro derivative 9, intermediate 24b obtained from Scheme 1C was fluorinated with 3,5-dichloro-1-fluoropyridinium triflate (25)<sup>6</sup> in refluxing methylene chloride to afford 26 (Scheme 1D). The triflate-reduction procedure and saponification shown in the scheme yielded retinoid 9. Reduction of the fluoro ketone intermediate with  $NaBH_4$  followed by saponification produced retinoid 16.

The synthesis of 5-methoxy- and 5-hydroxy-naphthoate retinoids 10 and 11 is shown in Scheme 2. 5-Amino-2-naphthol (27) was bisacetylated and selectively saponified to provide acetamide 28. The resulting phenol was converted to a methyl ester (29) through carbonylation of the corresponding triflate in the presence of palladium catalyst.<sup>7</sup> The acetamide was hydrolyzed and the amino group was transformed to a phenol (30) by diazotization<sup>8</sup> followed by hydrolysis.<sup>9</sup> Friedel-Crafts reaction of the methyl ether of 30 with 1.3 equiv of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid chloride (31) and 2 equiv of  $AlCl_3$  in nitromethane at 65 °C

smoothly provided 32. Saponification of the ester yielded 10. When 32 was treated with boron tribromide followed by saponification, the 5-hydroxy derivative 11 was obtained.

Scheme 2<sup>a</sup>

<sup>a</sup> (a) Ac<sub>2</sub>O, Pyr.; (b) NaOH; H<sup>+</sup>; (c) Ti<sub>2</sub>O, DMAP; (d) CO, Pd(OAc)<sub>2</sub>, dppp, Et<sub>3</sub>N, MeOH; (e) HCl-MeOH; (f) NaNO<sub>2</sub>, HBF<sub>4</sub>; (g) aq. H<sub>2</sub>SO<sub>4</sub>; (h) NaH, MeI; (i) 31, AlCl<sub>3</sub>; (j) NaOH; (k) BBr<sub>3</sub>.

All of the retinoids prepared were evaluated in the RAR transactivation assays.<sup>10</sup> For the substituted ketone derivatives 3-11, methoxy substitution at the 1 position of the 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene (TTN) ring of ketone 1 resulted in an inactive retinoid 4. Introduction of substituents such as OH, Me, and OMe at the 3-position of the TTN ring (retinoids 5, 6, and 8 respectively) also decreases activity. However, fluorination at the 1', 3', or 4' position of the TTN ring (3, 7, and 9) in general had only a slight effect on potency or receptor selectivity. These results seem to suggest that bulky substituents at the 1 and 3 positions of the TTN ring, which affect the dihedral angle of the TTN and the naphthoic acid ring, decrease the activity, while a smaller substituent like fluorine has a less effect on activity. In the naphthoic acid portion, compounds with methoxy or hydroxy substitution

Table 1. RAR Transactivation Assays of the Substituted 2-Naphthoic Acid Retinoids<sup>a</sup>


Compound Number	EC <sub>50</sub> <sup>b</sup>			% Max <sup>c</sup>		
	RAR-α	RAR-β	RAR-γ	RAR-α	RAR-β	RAR-γ
1	13	3	1.4	65	82	93
2	NA	133	14	0	77	95
3	100	6.7	15	46	87	92
4	NA	NA	NA	0	0	0
5	25	7.5	20	44	76	70
6	25	25	75	26	81	58
7	25	15	3	34	81	70
8	8	14	6	23	61	53
9	10	4	6.7	63	81	100
10	NA	NA	NA	0	0	0
11	NA	NA	NA	0	0	0
12	NA	133	15	0	74	90
13	NA	NA	30	0	18	47
14	NA	100	5.6	0	96	82
15	NA	133	100	0	30	70
16	NA	NA	NA	0	0	0

(a) Compounds were evaluated at concentrations ranging from 10<sup>-10</sup> to 10<sup>-6</sup> M. NA: not active. (b) The EC<sub>50</sub> ratio of each compound was obtained by dividing the concentration required to obtain 50% of the maximum transactivation activity of each compound with that of retinoic acid. (c) % Max is the maximum transactivation activity of the tested compound relative to that of retinoic acid at 10<sup>-6</sup> M.

at the 5-position (10 or 11), surprisingly gave no activity at all in the transactivation assays. For the alcohol derivatives of 2, 12-16, the SAR is very different from that of the ketone series described above. For instance, fluorination at the 1 position of the TTN ring (12) maintains the activity of 2. However, fluorination at 3 and 4 positions (15 and 16, respectively) dramatically decreases activity. On the other hand, a methyl substitution at the 3 position of the TTN ring has very little effect on the activity, indicating that the alcohol series might have better steric tolerance at this position. These results suggest that for ketone 1, the size of the substituents at the 1 and 3 position of the TTN ring has a very strong impact on the activity of ketone 1. However, such a steric effects seem to be less important in the alcohol series 2.

Because attempts to improve potency and the RAR receptor selectivity of 1 by the substituent modification described above were unsuccessful, we turned our attention to the modification of the keto linker of 1. The retinoids synthesized with varied heteroatom linkers (33-40) are shown in Chart 2.

Chart 2



Scheme 3A depicts the synthesis of the retinoids 33-36. The common intermediate for preparing these derivatives, methyl 6-bromo-2-naphthoate (41) was easily prepared from 6-bromo-2-naphthol by selective carbonylation of the corresponding triflate in the presence of palladium catalyst.<sup>8</sup> Bromide 41 was then displaced with either 2-thio-<sup>11</sup> or 2-amino-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene in the presence of *t*-BuOK and Pd(PPh<sub>3</sub>)<sub>4</sub>,<sup>12</sup> accompanied by hydrolysis of the methyl esters, to afford 33 and 36, respectively. Acid 33 was further treated with diazomethane to give the methyl ester which was oxidized with 1.05 equiv or 4 equiv of magnesium monoperoxyphthalate (MMPP),<sup>13</sup> followed by saponification to give the sulfoxide 34 and sulfone 35, respectively. The same strategy was used in an attempt to prepare the ether analogue 37 by coupling phenol 42 with methyl 6-bromo-2-naphthoate (41). However, this gave only recovered starting materials. Alternatively, Ullmann reaction<sup>14</sup> of 42 with 2-bromo-6-methoxynaphthalene (43) provided 44 (Scheme 3B). Methyl ether 44 was partially purified and subsequently treated with BBr<sub>3</sub> to give naphthol 45. Naphthol 45 was converted to an ester via triflate 46. Hydrolysis of the ester afforded ether retinoid 37. In a similar approach to prepare 33, 2-thio-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene reacted with 47<sup>15</sup> to give retinoid 38 (Scheme 3C). Oxidation of the sulfide ester of 38 with 4 equiv of MMPP afforded the ester of sulfone 40. However, when the sulfide was oxidized with 1.05 equivalents of MMPP, an inseparable mixture of sulfone and sulfoxide was obtained. Using milder reaction conditions, the sulfide was oxidized with sodium perborate<sup>16</sup> to cleanly give the sulfoxide ester. Saponification of the ester of the vinyl sulfoxide or sulfone provided retinoids 39 and 40, respectively.

The RAR transactivation activity of the heteroatom-linker retinoids is shown in Table 2. The results clearly indicate that the keto linker of 1 can be replaced with heteroatoms such as S, N, or O (e.g., 33, 36, and 37) without significant loss of the transactivation activity. Similarly, the vinyl sulfide retinoid (38) is more potent than Ch 80<sup>17</sup> in the transactivation assay. Notably, when the sulfur linker was oxidized to a sulfoxide or sulfone (e.g., 34, 35, 39, and

40), the  
retain I  
previou  
reductio

Sche

(A) B

(B)

(C)

B

a  
(a) Tf<sub>2</sub>C  
equiv;  
Pd(PPh<sub>3</sub>)<sub>4</sub>


Table

Comp	Nun
1	Ch
3	3
3	3
3	3
3	3
3	3
3	3
3	3
4	4

NA: no



40), the activity of the retinoids is dramatically reduced. Furthermore, we have found that these naphthoate retinoids retain RAR  $\beta$ ,  $\gamma$  selectivity, while the benzoate retinoid such as 38, is RAR non-selective. The results support our previous observation that the naphthoate ring of 1 is crucial for its RAR  $\beta$ ,  $\gamma$  activity.<sup>1</sup> In the in vivo utriculi reduction assay<sup>18</sup> (Figure 1), ketone 1 and sulfide 33 were shown to be as potent as retinoic acid (RA), while vinyl

Scheme 3<sup>a</sup>


<sup>a</sup> (a)  $\text{Ti}_2\text{O}_3$ , DIEA; (b) CO, MeOH,  $\text{Pd}(\text{OAc})_2$ , dppp; (c)  $\text{Pd}(\text{PPh}_3)_4$ ,  $t\text{-BuOK}$ ; (d)  $\text{CH}_2\text{N}_2$ ; (e) MMPP (1.05 equiv); (f) MMPP (4 equiv); (g) NaOH; (h) 43,  $\text{K}_2\text{C}_2\text{O}_3$ , pyr, Cu; (i)  $\text{BBr}_3$ ; (j) methyl *p*-bromobenzoate,  $\text{Pd}(\text{PPh}_3)_4$ ; (k)  $\text{Br}_2$ ; (l) 2-thio-TTN,  $\text{Pd}(\text{PPh}_3)_4$ ,  $t\text{-BuOK}$ ; m)  $\text{NaBO}_3$ .

Table 2. RAR Transactivation Assays of the Naphthoic Acid Retinoids 33-40.

Compound Number	EC50			% Max		
	RAR- $\alpha$	RAR- $\beta$	RAR- $\gamma$	RAR- $\alpha$	RAR- $\beta$	RAR- $\gamma$
1	13	3	1.4	65	82	93
Ch 80	0.7	1.2	1.0	100	91	98
33	25	10	2	45	88	83
34	NA	167	100	0	52	64
35	NA	133	100	0	32	64
36	25	17	15	27	92	91
37	63	20	8	56	120	78
38	1.3	0.8	0.2	118	158	77
39	38	40	8	42	96	64
40	NA	200	150	0	35	64

NA: not active

Figure 1. In Vivo Utricle Reduction of The Retinoids



sulfide 38 is more potent than Ch80 and causes skin peeling at concentrations above 0.03 mM. The results are consistent with that of the in vitro transactivation assay. RAR  $\beta$ ,  $\gamma$  selective retinoid 2, on the other hand, showed only one tenth the activity of ketone 1 in the assay.<sup>1</sup>

In summary, the substitution at varied positions of the aromatic rings of 1 and 2 produces no significant improvement in terms of potency or RAR selectivity. Nevertheless, these compounds in general still retain RAR  $\beta$ ,  $\gamma$  selectivity. In addition, we have found that the keto linker of 1 can be replaced with heteroatoms such as S, O, and N without significant reduction of the transactivation activity. Among these heteroatom linker retinoids, sulfide 33 is as active as ketone 1, and vinyl sulfide 38 is more potent than Ch80.

#### References:

1. Yu, K.-L.; Chen, S.; Ostrowski, J.; Tramposch, K. M.; Reczek, P. R.; Mansuri, M. M.; Starrett, J. E. Jr. The preceding paper in this Journal.
2. Cacchi, S.; Ciattini, P. G.; Morera, E.; Ortar, G. *Tetrahedron Lett.* 1986, 27, 5541.
3. Maignan, J.; Malle, M.; Deflandre, A.; Lang, G. Eur. Pat. Applic. 404 640, 1990; *Chem. Abstr.* 1991, 115, 91827.
4. Saa, J. M.; Dopico, M.; Martorell, G.; Garcia-Raso, A. *J. Org. Chem.* 1990, 55, 991.
5. Coutts, I. G. C.; Durbin, A. K.; Schofield, K. *Aust. J. Chem.* 1970, 23, 791.
6. Umemoto, T.; Fukami, S.; Tomizawa, G.; Harsawa, K.; Kawada, K.; Tomita, K. *J. Am. Chem. Soc.* 1990, 112, 8563.
7. Dolle, R. E.; Schmidt, S. J.; Kruse, L. I. *J. Chem. Soc. Chem. Commun.* 1987, 904.
8. Weinstein, S.; Heck, R. F. *J. Org. Chem.* 1972, 37, 825.
9. Starekey, E. B. *Org. Syn. Coll. Vol. II*, 1943, 225.
10. Brand, N.; Petkovich, M.; Krust, A.; Chambon, P.; de The, H.; Marchio, A.; Tiollais, P.; Dejean, A. *Nature (London)* 1988, 332, 850.
11. Janssen, B.; Wuest, H.-H. Eur. Pat. Appl. 386 452, 1990; *Chem. Abstr.* 1991, 114, 163780.
12. Migita, T.; Shimizu, T.; Asami, Y.; Shiobara, J.; Kato, Y.; Kosugi, M. *Bull. Chem. Soc. Jpn.* 1980, 53, 1385-1389.
13. Brougham, P.; Cooper, M. S.; Cummers, D. A.; Heaney, H.; Thompson, N. *Synthesis* 1987, 1015-1017.
14. Sawa, Y. K.; Tsuji, N.; Maeda, S. *Tetrahedron*, 1961, 15, 154.
15. Haack, R.; Penning, T. D.; Djuric, S. W.; Dziuba, J. A. *Tetrahedron Lett.* 1988, 29, 2783-2786.
16. McKillop, A.; Tarbin, J. A. *Tetrahedron Lett.* 1983, 24, 1505-1508.
17. Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. *J. Med. Chem.* 1989, 32, 834-840.
18. (a) Tramposch, K.M.; Nair, X.; Gendimenico, G. J.; Tetrault, G. B.; Chen, S.; Kiss, I.; Whiting, G.; Bonney, R. J. *J. Pharm. Pharmacol.* 1992, 44, 379. b) Chen, S.; Ostrowski, J.; Whiting, G.; Roalsvig, T.; Hammer, L.; Currier, S. J.; Honeyman, J.; Kwasniewski, B.; Yu, K.-L.; Sterzycki, R.; Kim, C. U.; Starrett, J. E. Jr.; Mansuri, M. M. and Reczek, P. R. *J. Invest. Dermatol.* 1995, 104, 779-783.

(Received in USA 14 May 1996; accepted 31 October 1996)